Company Analysis

Regentis Biomaterials Ltd. (RGNT)

NYSE: RGNT · Orthopedic, Prosthetic & Surgical Appliances & Supplies · filing with the SEC since 2022
Grade5.9
◀ Past 5.1● Present 5.4▶ Future 7.1
7 est.

Who runs Regentis Biomaterials Ltd.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Geller Ehud
Chief Executive Officer. First filing Mar 2026, latest Jul 13, 2026, 0 filings in all.
Officers reporting now
4
of 9 people with a filing in the last fifteen months
Directors reporting now
5
9 people on the record since 2026
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Geller EhudChief Executive OfficerMar 2026Jul 13, 2026none
Reske GalitChief Medical OfficerMar 2026Mar 30, 2026none
Gon OriChief Financial OfficerMar 2026Mar 18, 2026none
Gordashnikov ArieChief Accounting OfficerMar 2026Mar 18, 2026none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Alpert Susan Phd MddirectorMar 2026Jul 13, 2026none
Ben-Elazar PinidirectorMar 2026Jul 13, 2026none
Cohen-Arazi EfraimdirectorMar 2026Jul 13, 2026none
Dykan JeffdirectorMar 2026Jul 13, 2026none
Valentine KeithdirectorMar 2026Jul 13, 2026none

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton RGNT · research, not advice